CLRM-03. BGB-290 AND TEMOZOLOMIDE IN TREATING ISOCITRATE DEHYDROGENASE (IDH)1/2-MUTANT GRADE I-IV GLIOMAS â A NOVEL MODEL OF AYA TRIAL DEVELOPMENT AND DEPLOYMENT
Marks A, Bindra R. CLRM-03. BGB-290 AND TEMOZOLOMIDE IN TREATING ISOCITRATE DEHYDROGENASE (IDH)1/2-MUTANT GRADE I-IV GLIOMAS â A NOVEL MODEL OF AYA TRIAL DEVELOPMENT AND DEPLOYMENT. Neuro-Oncology Advances 2021, 3: iv1-iv1. PMCID: PMC8453774, DOI: 10.1093/noajnl/vdab112.002.Peer-Reviewed Original ResearchAdult Brain Tumor ConsortiumAYA populationAYA patientsClinical trialsIDH1/2 mutationsPatients ages 13Years of ageInternational clinical trialsYoung adult populationTemozolomide chemotherapyInitial dosingLack of enrollmentGrade IPsychosocial assessmentPARP inhibitor sensitivityUnique cohortDisease processMost trialsGlioma populationInternational trialTrial developmentAdult populationSpecific trialsPatientsTrials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply